Study designs for biosimilar switching: June 2019
| Bio-originator/biosimilar | Study design (phase) | Indication | Type of switch |
| Infliximab/CT-P13 (PLANETRA) | OL extension of DB RCT | RA | One way, bo→bs |
| Infliximab/CT-P13 (PLANETAS) | OL extension of DB RCT | AS | One way, bo→bs |
| Infliximab/CT-P13 | Observational single-centre study | RA, SpA, PsA, JIA, chronic reactive arthritis | One way, bo→bs |
| Infliximab/CT-P13 | Observational registry | RA, SpA, PsA, other (not defined) | One way, bo→bs |
| Infliximab/SB2 | DB RCT | RA | One way, bo→bs |
| Infliximab/biosimilar | Retrospective single-centre study | Inflammatory arthritis | One way, bo→bs |
| Infliximab/biosimilar | Multi-centre study | AS, PsA, SpA, enteropathic arthritis | One way, bo→bs |
| Etanercept/SB4 | SB crossover | - | One way, bo→bs; bs→bo |
| Etanercept/SB4 | OL extension of DB RCT | RA | One way, bo→bs |
| Etanercept/GP2015 | Two-way crossover | One way, bo→bs; bs→bo | |
| Adalimumab/SB5 | DB RCT | RA | One way, bo→bs |
| Rituximab/CT-P10 | OL extension of RCT | RA | One way, bo→bs |
AS, ankylosing spondylitis; bo, biologic originator; bs, biosimilar; DB, double blind; JIA, juvenile idiopathic arthritis; OL, open label; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RCT, randomised controlled trial; SB, single blind; SpA, spondyloarthritis.